|Issuer:||CLOVIS ONCOLOGY, INC. (CLVS)|
|Original Submission Date:|
HARDING THOMAS C.
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100 BOULDER, CO 80301
|Title of Security||Transaction Date||2a. Deemed Execution Date||Transaction Code||Shares||Acquired or Disposed||Price per share||5. Amount of Securities Beneficially Owned Following Reported Transaction||6. Ownership Form Direct or Indirect||Nature of Indirect Ownership|
|Title of Derivative Security||Conversion or Exercise Price of Derivative Security||Transaction Date||Deemed Execution Date||Transaction Code||Number of Derivative Securities Acquired (A) or Disposed of (D)||Date Exercisable||Expiration Date||Title and Amount of Securities Underlying Derivative Security||Price of Derivative Security||Number of derivative Securities Beneficially Owned Following Reported Transaction(s)||Ownership Form: Direct (D) or Indirect (I)||Nature of Indirect Beneficial Ownership|
|RESTRICTED STOCK UNITS||0.0||2021-07-01||deemed execution date||M||63 (a)||common stock 63||$0.00||187||indirect||by wife|
|f1||each restricted stock unit represents the right to receive one share of common stock.|
|f2||represents the shares automatically sold by the reporting person's wife pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the restricted stock units listed in table ii. this sale does not represent a discretionary trade by the reporting person.|
|f3||on july 1, 2020, the reporting person's wife was granted 250 restricted stock units. 25% of such restricted stock units vested on july 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.|